Loading organizations...
The Parker Institute for Cancer Immunotherapy (PICI) is a research organization dedicated to expediting breakthrough immune therapies for cancer. It operates as an active institute, engineered to overcome research barriers and foster deep collaboration among leading scientists. PICI's technical approach translates innovative scientific concepts into effective cancer treatments by leveraging the body's immune system.
PICI was established in 2016 by entrepreneur and philanthropist Sean Parker. His founding insight was that a unified, collaborative research ecosystem was critical to accelerate cancer immunotherapy. Parker’s vision aimed to bring together leading experts, revolutionizing research to expedite the discovery of life-saving treatments for patients.
PICI primarily benefits cancer patients globally and the scientific and medical communities through its innovations. The institute's mission is to develop and implement breakthrough immune therapies, with the ultimate vision of rendering all cancers curable diseases. It pursues this ambitious goal via its unique collaborative operational model.
Key people at Parker Institute for Cancer Immunotherapy.
Parker Institute for Cancer Immunotherapy was founded in 2016 by Sean Parker (Founder and Chairman).
Parker Institute for Cancer Immunotherapy has 1 tracked investment across 1 company. The latest tracked deal is $100.0M Series A in Tmunity Therapeutics in January 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 23, 2018 | Tmunity Therapeutics | $100.0M Series A | — | AMY Ronneberg, Gilead Sciences, Lilly Asia Ventures, Jiang Zhang, University OF Pennsylvania |
Parker Institute for Cancer Immunotherapy was founded in 2016 by Sean Parker (Founder and Chairman).
Key people at Parker Institute for Cancer Immunotherapy.
